glut inhibitor drb18  (MedChemExpress)

Journal: Biochemistry and Biophysics Reports

Article Title: Dimethyl-2-oxoglutarate but not antioxidants prevents glucose hypometabolism induced neural cell death: implications in the pathogenesis and therapy of Alzheimer's disease

doi: 10.1016/j.bbrep.2025.102150

Figure Lengend Snippet: DRB18 induced death of SH-SY5Y cells SH-SY5Y cells were incubated for 48 h in CO 2 incubator at 37 0 C and subsequently analysed for cell death or ROS production; cells were untreated (control) or treated with various concentrations of DRB18 or DRB18 (20 μM) plus other additions such as ferrostatin-1 (Fer-1, 1 μM) or liproxstatin −1 (Lip-1, 1 μM) or pyruvate (5 mM) or succinate (5 mM) or glutamate (5 mM). A, D, F: Cell death measured by released LDH assay; B: ROS production by H 2 DCFDA assay; C, E: cell death by Trypan blue method. Values (means ± SD) are from 6 independent observations (biological replicates). One-way ANOVA was performed followed by post-hoc Tukey's test; p < 0.05 was considered statistically significant.

Article Snippet: For experimental purposes, the cells were either untreated (control) or treated with the GLUT-inhibitor DRB18 (MedChemExpress, USA, Cat No. HY-145963) with varying concentrations (5–40 μM) for 48 h at 37 0 C. Additionally for some experiments, DRB18 treated cells were co-treated with any of the other compounds such as ferrostatin-1 (1 μM, Sigma, USA, Cat No. SML0583), liproxstatin-1 (1 μM, Sigma, USA, Cat No. SML1414), N-acetylcysteine (2.5 mM, Sigma, USA, Cat No. A9165), pyruvate (5 mM, SRL, India, Cat No. 23569), succinate (5 mM SRL, India, Cat No. 87578), glutamate (5 mM, SRL, India, Cat No. 23229) and dimethyl-2-oxoglutarate or DMO (5 mM, Sigma, USA, 349631).

Techniques: Incubation, Control, Lactate Dehydrogenase Assay

Journal: Biochemistry and Biophysics Reports

Article Title: Dimethyl-2-oxoglutarate but not antioxidants prevents glucose hypometabolism induced neural cell death: implications in the pathogenesis and therapy of Alzheimer's disease

doi: 10.1016/j.bbrep.2025.102150

Figure Lengend Snippet: DMO prevents cell death and mitochondrial impairment in SH-SY5Y cells SH-SY5Y cells were untreated (control) or treated with DRB18 (20 μM) or DRB18 (20 μM) plus DMO (5 mM) for 48 h as described in the Experimental Procedures. Cell death was assessed by Trypan blue assay (A) or LDH activity released in the medium (B). Mitochondrial membrane potential was measured by TMRE assay (C), intra-cellular ATP content by luciferin-luciferase assay (D) and ROS by H 2 DCFDA assay (E). Values represent means ± SD, n = 6 for A and B; n = 7 for C, n = 8 for D, n = 6 for E (n represents the number of independent biological replicates) One-way ANOVA with Tukey's post-hoc test was performed; p < 0.05 was taken as significant.

Article Snippet: For experimental purposes, the cells were either untreated (control) or treated with the GLUT-inhibitor DRB18 (MedChemExpress, USA, Cat No. HY-145963) with varying concentrations (5–40 μM) for 48 h at 37 0 C. Additionally for some experiments, DRB18 treated cells were co-treated with any of the other compounds such as ferrostatin-1 (1 μM, Sigma, USA, Cat No. SML0583), liproxstatin-1 (1 μM, Sigma, USA, Cat No. SML1414), N-acetylcysteine (2.5 mM, Sigma, USA, Cat No. A9165), pyruvate (5 mM, SRL, India, Cat No. 23569), succinate (5 mM SRL, India, Cat No. 87578), glutamate (5 mM, SRL, India, Cat No. 23229) and dimethyl-2-oxoglutarate or DMO (5 mM, Sigma, USA, 349631).

Techniques: Control, Activity Assay, Membrane, Luciferase